search
Back to results

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Primary Purpose

Schizoaffective Disorder, Schizophrenia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
IM risperidone
oral antipsychotic medication
Sponsored by
US Department of Veterans Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizoaffective Disorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 years or older. Diagnosed with schizophrenia or schizoaffective disorder by the Structured Clinical Interview for Diagnosis (SCID) (Spitzer and First et al., 1996). Patients should have been hospitalized in the two years before study entry on a psychiatric inpatient unit, or document explicit current evidence of increased use of outpatient services such as additional visits, day treatment or non-hospital residential treatment, increased dosage of medications or addition of concomitant psychotropic medications. The b criterion will promptly be adjudicated by the study chairmen on a case-by case basis to insure credibility. .Adequate transportation is available and the participant lives within a travel time of less than 1.5 hours, allowing attendance at all scheduled visits. Use of an acceptable method of birth control by female patients who have a possibility of becoming pregnant (safety concerns). Able to demonstrate decisional capacity in order to give informed consent as assessed by the MacArthur Competence Assessment Tool (MacCAT) (Appelbaum and Grisso, 1996). Guardian consent is acceptable where applicable. Dually diagnosed patients with both schizophrenia and addictive disorders would be included in this study but should not be in need of acute detoxification for physiologic substance dependence (excluding nicotine) in the past 30 days. Exclusion Criteria: Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion). Intolerance of risperidone. Intolerance of intramuscular injection. Current treatment with depot antipsychotic medication. Current treatment with oral clozapine or presence of refractory schizophrenia that, in the treating psychiatrist's opinion, requires clozapine. Hepatic or renal problems AST or ALT (>2 times upper limit of normal); Elevated bilirubin (>1.2), BUN (>24), creatinine (>1.7). Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care. Dementia, epilepsy, insulin-dependent diabetes, anticoagulation with coumadin. Unstable living arrangements or not planning to remain in the area for the next year. Legal entanglements or pending legal charges with potential of incarceration. Assault or suicide gesture currently needing acute intervention. Concurrent participation in another clinical trial with an investigational drug during the last 30 days. Pregnant or lactating women or women planning to become pregnant.

Sites / Locations

  • VA Medical Center, Tuscaloosa
  • VA Medical Center, Long Beach
  • VA Palo Alto Health Care System
  • VA Connecticut Health Care System (West Haven)
  • VA Medical Center, Miami
  • VA Medical Center, Augusta
  • Jesse Brown VAMC (WestSide Division)
  • VA Medical Center, Jamaica Plain Campus
  • John D. Dingell VA Medical Center, Detroit
  • VA Medical Center, Minneapolis
  • VA Medical Center, Kansas City MO
  • VA Medical Center, Omaha
  • New Mexico VA Health Care System, Albuquerque
  • New York Harbor HCS
  • VA Medical Center, Cleveland
  • VA Medical Center, Philadelphia
  • Michael E. DeBakey VA Medical Center (152)
  • Central Texas Veterans Health Care System - Waco
  • VA Puget Sound Health Care System, Seattle

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm 1

Arm 2

Arm Description

long-acting injectable risperidone

oral antipsychotic medication

Outcomes

Primary Outcome Measures

Hospitalization-free Survival - Time to Event
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. Patients without an event were censored at 24 months after the date of randomization.
Hazard Ratio for Hospitalization
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model.

Secondary Outcome Measures

Full Information

First Posted
August 17, 2005
Last Updated
October 30, 2013
Sponsor
US Department of Veterans Affairs
search

1. Study Identification

Unique Protocol Identification Number
NCT00132314
Brief Title
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Official Title
CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
US Department of Veterans Affairs

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to long-acting injectable risperidone or doctor's choice of oral antipsychotic medication (i.e., excluding other long-acting injectable medications, but not specifying any particular oral agents or dosages). Recruitment would take 27 months to complete, and the study would continue for a third year to allow 9 months of follow-up for the last patient recruited. All patients would be treated from the time of entry up to the end of the three-year study period. Follow-up assessments would continue quarterly. Treatments would not be blinded since giving placebo injections to the comparison group would interfere with the goal of comparing the acceptability of two different methods of medication administration. However, end points will be blindly rated.
Detailed Description
The purpose of the study is to assess the effectiveness of long-acting injectable risperidone on psychiatric inpatient hospitalization, schizophrenia symptoms, quality of life, medication adherence, side effects, and health care costs. Objectives: Primary: To evaluate the impact of long-acting intramuscular (IM) risperidone on risk of inpatient psychiatric hospitalization in comparison to standard oral antipsychotic treatment in a randomized controlled trial to be conducted with 450 veterans diagnosed with schizophrenia or schizoaffective disorder at 16 VA medical centers over three years. Secondary: To evaluate adherence, health benefits, and costs of long-acting IM risperidone as compared to standard oral antipsychotic treatment as measured by: a) symptom reduction over 12 months, b) time to all-cause medication discontinuation, c) quality of life, d) VA and non-VA health service use and related costs, e) medication side effects, f) violent behavior, g) use of concomitant medication, and h) the incremental cost-effectiveness ratio.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizoaffective Disorder, Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
382 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Arm Description
long-acting injectable risperidone
Arm Title
Arm 2
Arm Type
Active Comparator
Arm Description
oral antipsychotic medication
Intervention Type
Drug
Intervention Name(s)
IM risperidone
Intervention Description
long-acting injectable risperidone
Intervention Type
Drug
Intervention Name(s)
oral antipsychotic medication
Intervention Description
doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
Primary Outcome Measure Information:
Title
Hospitalization-free Survival - Time to Event
Description
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. Patients without an event were censored at 24 months after the date of randomization.
Time Frame
From randomization until date of first re-hospitalization, assessed up to 24 months
Title
Hazard Ratio for Hospitalization
Description
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older. Diagnosed with schizophrenia or schizoaffective disorder by the Structured Clinical Interview for Diagnosis (SCID) (Spitzer and First et al., 1996). Patients should have been hospitalized in the two years before study entry on a psychiatric inpatient unit, or document explicit current evidence of increased use of outpatient services such as additional visits, day treatment or non-hospital residential treatment, increased dosage of medications or addition of concomitant psychotropic medications. The b criterion will promptly be adjudicated by the study chairmen on a case-by case basis to insure credibility. .Adequate transportation is available and the participant lives within a travel time of less than 1.5 hours, allowing attendance at all scheduled visits. Use of an acceptable method of birth control by female patients who have a possibility of becoming pregnant (safety concerns). Able to demonstrate decisional capacity in order to give informed consent as assessed by the MacArthur Competence Assessment Tool (MacCAT) (Appelbaum and Grisso, 1996). Guardian consent is acceptable where applicable. Dually diagnosed patients with both schizophrenia and addictive disorders would be included in this study but should not be in need of acute detoxification for physiologic substance dependence (excluding nicotine) in the past 30 days. Exclusion Criteria: Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion). Intolerance of risperidone. Intolerance of intramuscular injection. Current treatment with depot antipsychotic medication. Current treatment with oral clozapine or presence of refractory schizophrenia that, in the treating psychiatrist's opinion, requires clozapine. Hepatic or renal problems AST or ALT (>2 times upper limit of normal); Elevated bilirubin (>1.2), BUN (>24), creatinine (>1.7). Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care. Dementia, epilepsy, insulin-dependent diabetes, anticoagulation with coumadin. Unstable living arrangements or not planning to remain in the area for the next year. Legal entanglements or pending legal charges with potential of incarceration. Assault or suicide gesture currently needing acute intervention. Concurrent participation in another clinical trial with an investigational drug during the last 30 days. Pregnant or lactating women or women planning to become pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert A. Rosenheck, AB MD
Organizational Affiliation
VA Connecticut Health Care System (West Haven)
Official's Role
Study Chair
Facility Information:
Facility Name
VA Medical Center, Tuscaloosa
City
Tuscaloosa
State/Province
Alabama
ZIP/Postal Code
35404
Country
United States
Facility Name
VA Medical Center, Long Beach
City
Long Beach
State/Province
California
ZIP/Postal Code
90822
Country
United States
Facility Name
VA Palo Alto Health Care System
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304-1290
Country
United States
Facility Name
VA Connecticut Health Care System (West Haven)
City
West Haven
State/Province
Connecticut
ZIP/Postal Code
06516
Country
United States
Facility Name
VA Medical Center, Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33125
Country
United States
Facility Name
VA Medical Center, Augusta
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
Jesse Brown VAMC (WestSide Division)
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
VA Medical Center, Jamaica Plain Campus
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02130
Country
United States
Facility Name
John D. Dingell VA Medical Center, Detroit
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
VA Medical Center, Minneapolis
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55417
Country
United States
Facility Name
VA Medical Center, Kansas City MO
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64128
Country
United States
Facility Name
VA Medical Center, Omaha
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68105-1873
Country
United States
Facility Name
New Mexico VA Health Care System, Albuquerque
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87108-5153
Country
United States
Facility Name
New York Harbor HCS
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States
Facility Name
VA Medical Center, Cleveland
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
VA Medical Center, Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Michael E. DeBakey VA Medical Center (152)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Central Texas Veterans Health Care System - Waco
City
Waco
State/Province
Texas
ZIP/Postal Code
76711
Country
United States
Facility Name
VA Puget Sound Health Care System, Seattle
City
Seattle
State/Province
Washington
ZIP/Postal Code
98108
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21270143
Citation
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH; CSP 555 Research Group. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials. 2011 Apr;8(2):196-204. doi: 10.1177/1740774510392931. Epub 2011 Jan 26.
Results Reference
result
PubMed Identifier
21366475
Citation
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011 Mar 3;364(9):842-51. doi: 10.1056/NEJMoa1005987. Erratum In: N Engl J Med. 2011 Mar 31;364(13):1281.
Results Reference
result
PubMed Identifier
21514794
Citation
Barnett PG, Scott JY, Rosenheck RA; CSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res. 2011 Aug;130(1-3):34-9. doi: 10.1016/j.schres.2011.03.033. Epub 2011 Apr 22.
Results Reference
result
PubMed Identifier
22697193
Citation
Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.
Results Reference
result
PubMed Identifier
23473656
Citation
Thwin SS, Hermes E, Lew R, Barnett P, Liang M, Valley D, Rosenheck R. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res. 2013 Oct 30;209(3):291-6. doi: 10.1016/j.psychres.2013.01.016. Epub 2013 Mar 7.
Results Reference
result
PubMed Identifier
23143523
Citation
Hoblyn JC, Rosenheck RA, Leatherman S, Weil L, Lew R; CSP 555 Investigator Group. Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatr Q. 2013 Jun;84(2):209-18. doi: 10.1007/s11126-012-9240-4.
Results Reference
derived

Learn more about this trial

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

We'll reach out to this number within 24 hrs